Moderna publishes Phase III Covid-19 vaccine study protocol as trial enrolls more than 80% of participants
The company said at its R&D day that the Phase III COVE trial of mRNA-1273 had enrolled 25,296 of its planned 30,000 participants, while slightly more than 10,000 had received the first and second doses of the vaccine.